Myocarditis and mRNA COVID-19 Vaccines: New Information from the CDC

According to the CDC (Center for Disease Control and Prevention), even though rare, a relationship between myocarditis and mRNA COVID-19 Vaccines definitely exists. Such risk is more prevalent among men, teenagers and young adults a few days following the second dose. 

Síntomas persistentes post COVID-19: mucho más frecuentes de lo que creíamos

Globally, the risk is low: 4.4 of cases per million after the first dose and 12.6 cases per million after the second. When considering only women, the risk is 4.7 cases per million, while in men, it is approximately 6 times more likely, with 32 cases per million.

For the second group of technicians monitoring COVID-19 vaccine safety, at present, the risk/benefit ratio clearly favors teenagers and young adults. 

By mid-June 1226 cases of myocarditis/pericarditis had been reported, possibly associated to vaccination. Mean age was 30, and 66% were men, with symptom onset within 4 days after vaccination. Less than half these cases have been effectively linked to vaccination, while the rest continue under scrutiny. 

80% has seen complete recovery and only 9 are still hospitalized at the time of this report. 

This has sparked social debate, since it is precisely the young who present the lowest risk of hospitalization or death in case of infection. 


Read also: Direct TAVR vs. Predilation: Potential Cost of a Simpler Procedure.


However, with most of the elder population already vaccinated, it is now when the virus is spreading amongst the young. 

To get an idea of the risk/benefit ratio, we should bear in mind that for every million men between 18 and 24 who get vaccinated, we prevent around 12,000 COVID-19 cases, 530 hospitalizations, 127 ICU cases and 3 deaths, vs. around 30 myocarditis cases. These figures leave no doubt about the benefit of vaccination. For women of this same age, we should prevent the same number of events vs. only 4 or 5 cases of myocarditis. 

This without taking into account cases of systemic multi-inflammatory syndrome in children and post COVID-19 symptoms (fatigue, insomnia, rhinorrhea, muscle pain, headache, lack of concentration, exercise intolerance, dyspnea and chest pain.).


Read also: Bifurcations: A Long Return Journey.


Vaccinating the young leads to lower community transmission and that should protect against spreading and new variants. 

Original Title: Myocarditis and Pericarditis Following mRNA COVID-19 Vaccination Updated June 23, 2021.

Reference: https://www.cdc.gov/coronavirus/2019-ncov/vaccines/safety/myocarditis.html.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

Is the Booster Dose Against COVID-19 Effective for All Ages?

The answer is incontrovertible: it is undeniably effective. For all ages, the confirmed COVID19 and severe case rates were significantly lower for patients who...

Pfizer Booster Dose Efficacy against Omicron

The BNT162b2 vaccine (Pfizer/BioNTech) has previously shown a 95% efficacy against COVID-19. This efficacy has been changing with the surge of new variants and,...

Once Again, the Omicron Variant Tests the Limits of Healthcare Systems, But with Hope

The latest significant COVID-19 variant, the Omicron, is again pushing healthcare systems around the world onto the verge of collapse, having reached over 300...

The Most Read Articles of 2021: COVID-19

A new year is coming to an end and at SOLACI we are going over the most read studies on our website, on COVID-19. Follow...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Sievers Type 1 Bicuspid Valves: Which to Use?

One of the current challenges in TAVR is bicuspid aortic valves (BAV), because of their anatomical complexity, calcification, raphe presence, aortic dilation and associated...

AHA 2024 | VANISH2 Trial

Cardiac defibrillator implants (CDIs) have been shown to improve survival in patients with ischemic cardiomyopathy and ventricular tachycardia (VT). However, approximately one third of...

AHA 2024 | SUMMIT

It has been previously shown that the pharmacological treatment of obesity (semaglutide) can reduce cardiovascular events in patients with cardiac failure (CF) and preserved...